Header Logo

Connection

Philip Bonomi to Morpholines

Back to Details
This is a "connection" page, showing publications Philip Bonomi has written about Morpholines.
Philip Bonomi
Connection Strength
0.302
Morpholines
  1. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol. 2007 Sep 01; 25(25):3936-44.
    View in: PubMed
    Score: 0.302
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.